BriaCell Therapeutics (NASDAQ:BCTX) Trading Up 5.4% – Time to Buy?

BriaCell Therapeutics Corp. (NASDAQ:BCTX)’s share price was up 5.4% during trading on Wednesday . The company traded as high as $0.62 and last traded at $0.60. Approximately 623,193 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 1,563,530 shares. The stock had previously closed at $0.57.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of BriaCell Therapeutics in a research report on Thursday, October 3rd.

BriaCell Therapeutics Stock Performance

The firm’s 50-day moving average is $0.78 and its two-hundred day moving average is $0.98. The stock has a market cap of $21.59 million, a P/E ratio of -0.51 and a beta of 1.39.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.45. As a group, research analysts forecast that BriaCell Therapeutics Corp. will post -0.58 EPS for the current year.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics as of its most recent filing with the SEC. 15.42% of the stock is currently owned by institutional investors.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.